

101758672 07c


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Attention: Certificate of Correction Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Filed: May 18, 2007

Signature:

Lynn L. Jansilis
(Lynn L. Jansilis)

Docket No.: 01017/35966B
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Letters Patent of:
Hui-Quan Han et al.

Patent No.: 7,179,625

Issued: February 20, 2007

For: HUMAN E3 α UBIQUITIN LIGASE FAMILY

**REQUEST FOR CERTIFICATE OF CORRECTION
PURSUANT TO 37 CFR 1.323**

Attention: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**Certificate
MAY 25 2007
of Correction**

Dear Sir:

Upon reviewing the above-identified patent, Patentee noted typographical errors which should be corrected.

In the Drawings:

In the Amendment dated May 30, 2006, page 20, Fig. 9, left graph label, Applicant error, "Gastroenmius" should be -- Gastrocnemius --.

In the Specification:

At page 2, line 16, Applicant error, "conjugatin" should be -- conjugation --.

At page 10, line 5, Applicant error, "cacheixia" should be -- cachexia --.

05/22/2007 TBESHAH1 00000062 7179625

01 75.1811

100.00 0P

At page 10, line 16, Applicant error, "does-dependent" should be -- dose-dependent --.

MAY 25 2007

At page 11, line 2, Applicant error, "molecules" should be -- molecule --.

At page 12, line 19, Applicant error, "encompasses" should be -- encompass --.

At page 15, line 14, Applicant error, "agents" should be -- agent --.

At page 15, line 33, PTO error, "tinder" should be -- under --.

At page 16, line 1, Applicant error, "0.01 5M" should be -- 0.015 M --.

At page 19, line 11, Applicant error, "a its hydropathic" should be -- a hydropathic --.

At page 21, line 21, Applicant error, "IN" should be -- In --.

At page 25, line 5, PTO error, "derivative" should be -- derivatize --.

At page 28, line 19, PTO error, "(I)" should be -- (1) --.

At page 29, line 8, PTO error, "normative" should be -- nonnative --.

At page 35, line 1, PTO error, "stricture" should be -- structure --.

At page 44, line 12, Applicant error, "La Jolla" should be -- La Jolla, --.

At page 44, line 32, Applicant error, "Univeristy Boulavard" should be -- University Boulevard --.

At page 48, line 13, PTO error, "call be" should be -- can be --.

At page 49, line 8, PTO error, "Synthesis." should be -- *Synthesis*, --.

At page 49, line 20, Applicant error, " example, using an" should be -- example, an --.

In the Amendment dated January 15, 2004, page 4, line 12, Applicant error, “molecule” should be -- molecules --.

At page 53, line 1, PTO error, “humanized” should be -- humanized, --.

At page 54, line 1, PTO error, “1536” should be -- 1536, --.

At page 59, line 2, Applicant error, “set of has” should be -- set of test molecules has --.

At page 62, line 18, Applicant error, “construct can” should be -- construct that can --.

At page 62, line 18, Applicant error, “vector(such as the pAS2-1 form Clontech)” should be -- vector (such as the pAS2-1 from Clontech) --.

At page 66, line 17, PTO error, “difluisal” should be -- diflunisal --.

At page 67, line 19, Applicant error, “pyrazalones” should be -- pyrazolones --.

At page 68, line 1, PTO error, “AFPS60” should be -- AFP860 --.

At page 70, line 3, PTO error, “cephalosporilns” should be -- cephalosporins --.

At page 72, line 14, Applicant error, “huE3 α such” should be -- such huE3 α --.

At page 73, line 12, PTO error, “pH typically” should be -- pH, typically --.

At page 74, line 11, PTO error, “maybe” should be -- may be --.

At page 76, line 22, PTO error, “19811” should be -- 1981 --.

At page 77, line 20, Applicant error, “pharmaceuticalcompositions” should be -- pharmaceutical compositions --.

At page 77, line 34, PTO error, “iii vitro” should be -- *in vitro* --.

At page 91, line 20, Applicant error, “clone of was” should be -- clone was --.

At page 92, line 2, Applicant error, “activities” should be -- activity --.

At page 94, line 12, Applicant error, “*Edition*”, *Edition*,” should be -- *Edition*,

--.

At page 94, line 15, Applicant error, “an recombinant” should be -- in recombinant --.

At page 95, line 23, Applicant error, “concentrations” should be -- concentration --.

At page 97, line 22, Applicant error, “manufacture’s” should be -- manufacturer’s --.

At page 98, line 9, Applicant error, “50 ug/ml” should be -- 50 µg/ml --.

At page 98, line 16, Applicant error, “PhosphaImager” should be -- a PhosphaImager --.

At page 98, line 31, Applicant error, “MgCl2” should be -- MgCl₂ --.

At page 99, line 3, Applicant error, “Phsophoimager” should be -- PhosphaImager --.

At page 100, line 28, Applicant error, “MgCl2” should be -- MgCl₂ --.

At page 100, line 30, Applicant error, “muscles” should be -- muscle --.

At page 101, line 7, Applicant error, “protein ubiquitination” should be -- protein ubiquitination --.

At page 101, line 31, Applicant error, “50-58 °C for 45 seconds, and 72°C for 1 minutes” should be -- 50-58°C for 45 seconds, and 72°C for 1 minute --.

At page 101, line 32, Applicant error, “avaiblae” should be -- available --.

At page 101, line 32, Applicant error, “1578553,)” should be -- 1578553) --.

At page 102, line 26, Applicant error, “was” should be -- were --.

At page 102, line 34, Applicant error, “were” should be -- was --.

At page 103, line 10, Applicant error, “seperating” should be -- separating --.

At page 103, lines 17-18, Applicant error, “SEQ ID NO: 29)” should be -- (SEQ ID NO: 29) --.

At page 103, line 19, Applicant error, “minutes” should be -- minute --.

At page 103, line 20, Applicant error, “Mannheim cat: 1578553,” should be -- Mannheim, cat: 1578553 --.

At page 103, line 30, Applicant error, “tehrere” should be -- there --.

At page 104, line 1, Applicant error, “decease” should be -- decrease --.

At page 105, line 31, Applicant error, “is critical” should be -- is a critical --.

In the Claims:

In the Amendment dated May 8, 2006, page 5, Claim 14, lines 7-8, PTO error, “least percent” should be -- least 95 percent --.


The errors were found both in the application as filed by Patentee and by the PTO. Therefore, our check in the amount of \$100.00 covering the fee set forth in 37 C.F.R. § 1.20(a) is enclosed. The errors now sought to be corrected are inadvertent typographical errors, the correction of which does not involve new matter or require reexamination.

Transmitted herewith is a proposed Certificate of Correction effecting such amendment. Patentee respectfully solicits the granting of the requested Certificate of Correction.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 01017/35966B.

Dated: May 18, 2007

Respectfully submitted,

By 
Lynn L. Janulis

Registration No.: 53,066
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Agent for Applicants

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 4

PATENT NO. : 7,179,625
APPLICATION NO. : 10/758,672
ISSUE DATE : February 20, 2007
INVENTOR(S) : Hui-Quan Han et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Drawings:

At Sheet 20, Fig. 9, left graph label, "Gastroenmius" should be -- Gastrocnemius --.

In the Specification:

At Column 2, line 2, "conjugatin" should be -- conjugation --.

At Column 7, line 3, "cacheixia" should be -- cachexia --.

At Column 7, lines 19-20, "does-dependent" should be -- dose-dependent --.

At Column 7, line 41, "molecules" should be -- molecule --.

At Column 8, line 42, "encompasses" should be -- encompass --.

At Column 10, line 28, "agents" should be -- agent --.

At Column 10, line 56, "tinder" should be -- under --.

At Column 10, line 58, "0.01 5M" should be -- 0.015 M --.

At Column 13, line 6, "a its hydropathic" should be -- a hydropathic --.

At Column 14, line 42, "IN" should be -- In --.

At Column 17, line 22, "derivative" should be -- derivatize --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Lynn L. Janulis
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357

1

FEB 25 2007

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Page 2 of 4

At Column 19, line 33, "(I)" should be -- (1) --.

At Column 19, lines 63-64, "normative" should be --nonnative --.

At Column 23, line 18, "stricture" should be -- structure --.

At Column 29, line 39, "La Jolla" should be -- La Jolla, --.

At Column 29, line 66, "Univeristy Boulavard" should be -- University Boulevard --.

At Column 32, line 28, "call be" should be -- can be --.

At Column 33, line 3, "Synthesis." should be -- *Synthesis*, --.

At Column 33, line 20, " example, using an" should be -- example, an --.

At Column 34, line 63, "molecule" should be -- molecules --.

At Column 35, line 50, "humanized" should be -- humanized, --.

At Column 36, line 31, "1536" should be -- 1536, --.

At Column 40, line 5, "set of has" should be -- set of test molecules has --.

At Column 42, line 31, "construct can" should be -- construct that can --.

At Column 42, line 32, "vector(such as the pAS2-1 form Clontech)" should be -- vector
(such as the pAS2-1 from Clontech) --.

At Column 45, line 21, "difluisal" should be -- diflunisal --.

At Column 46, lines 6-7, "pyrazalones" should be -- pyrazolones --.

At Column 46, line 31, "AFPS60" should be -- AFP860 --.

At Column 47, line 65, "cephalosporilns" should be -- cephalosporins --.

At Column 49, line 44, "huE3α such" should be -- such huE3α --.

At Column 50, line 20, "pH typically" should be -- pH, typically --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Lynn L. Janulis

MARSHALL, GERSTEIN & BORUN LLP

2

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

MAY 25 2007

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Page 3 of 4

At Column 50, line 64, "maybe" should be -- may be --.

At Column 52, line 43, "19811" should be -- 1981 --.

At Column 53, lines 19-20, "pharmaceuticalcompositions" should be -- pharmaceutical compositions --.

At Column 53, line 38, "iii vitro" should be -- *in vitro* --.

At Column 63, line 17, "clone of was" should be -- clone was --.

At Column 63, lines 41-42, "activities" should be -- activity --.

At Column 65, lines 13-14, "*Edition*", *Edition*," should be -- *Edition*, --.

At Column 65, line 17, "an recombinant" should be -- in recombinant --.

At Column 66, line 6, "concentrations" should be -- concentration --.

At Column 67, line 32, "manufacture's" should be -- manufacturer's --.

At Column 67, line 61, "50 ug/ml" should be -- 50 µg/ml --.

At Column 68, line 3, "Phosphalmager" should be -- a Phosphalmager --.

At Column 68, line 23, "MgCl2" should be -- MgCl₂ --.

At Column 68, line 32, "Phsophoimager" should be -- Phosphalmager --.

At Column 69, line 47, "MgCl2" should be -- MgCl₂ --.

At Column 69, line 51, "muscles" should be -- muscle --.

At Column 69, line 64, "protein ubquitination" should be -- protein ubiquitination --.

At Column 70, line 31, "50-58 °C for 45 seconds, and 72°C for 1 minutes" should be -- 50-58°C for 45 seconds, and 72°C for 1 minute --.

At Column 70, line 31, "avaiblae" should be -- available --.

At Column 70, line 32, "1578553," should be -- 1578553 --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Lynn L. Janulis

MARSHALL, GERSTEIN & BORUN LLP

3

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

MAY 25 2007

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**Page 4 of 4

At Column 71, line 2, "was" should be -- were --.

At Column 71, line 13, "were" should be -- was --.

At Column 71, line 28, "seperating" should be -- separating --.

At Column 71, lines 38-39, "SEQ ID NO: 29)" should be -- (SEQ ID NO: 29) --.

At Column 71, line 40, " minutes" should be -- minute --.

At Column 71, lines 41-42, "Mannheim cat: 1578553," should be -- Mannheim, cat:
1578553 --.

At Column 71, line 58, "tehrere" should be -- there --.

At Column 71, line 62, "decease" should be -- decrease --.

At Column 74, line 2, "is critical" should be -- is a critical --.

In the Claims:

At Column 165, line 47, "least percent" should be -- least 95 percent --.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Attention: Certificate of Correction Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: May 18, 2007

Signature:  (Lynn L. Janulis)

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Lynn L. Janulis

MARSHALL, GERSTEIN & BORUN LLP

4

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

MAY 25 2007